IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ET
IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ET
TORONTO and GLIL YAM, Israel, Aug. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2024 ended June 30, 2024, on Wednesday, August 14, 2024, before the market opens.
医疗大麻公司Im Cannabis Corp.（CSE：IMCC）（纳斯达克：IMCC）（以下简称“公司”、“IMCannabis”或“IMC”）是一家领先的医疗大麻公司，在以色列和德国开展业务。将于2024年8月14日星期三市场开盘前公布2024年第二季度截至2024年6月30日的运营和财务结果。
The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.
公司将于同一天早上9:00（美东时间）举行Zoom网络研讨会，讨论结果，并为投资者答疑解惑。我们诚挚地邀请投资者通过点击此处来注册。所有相关信息将在注册后发送。
If you are unable to join us live, a recording of the call will be available on our website at within 24 hours after the call.
如果您无法参加直播，我们会在通话结束后24小时内在我们的网站上提供通话的录音。
Link for the to register for the zoom call:
Zoom call注册链接：
About IM Cannabis Corp.
关于IM大麻股份有限公司。
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
IMC（纳斯达克：IMCC）（CSE：IMCC）是一家国际大麻公司，在以色列和德国这两个最大的医用大麻市场为患者提供高档大麻产品。公司专注于在最有价值的市场，即以色列和德国实现可持续和盈利性增长。公司利用跨国生态系统，通过独特的数据驱动方法和全球供应链来推动。公司始终致力于负责任的增长，并遵守最严格的监管环境，努力扩大其商业和品牌实力，成为全球高质量的大麻企业。
The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
IMC生态系统通过Focus Medical Herbs Ltd.在以色列运营，该公司利用多年的专有数据和病人见解向医疗患者进口和分销大麻。公司还在以色列经营医疗大麻零售药店、在线平台、分销中心和物流中心，以确保在整个价值链上提供安全交付和质量控制IMC产品。在德国，IMC生态系统通过Adjupharm GmbH运营，向大麻药房分销大麻，为医用大麻患者提供帮助。
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
公司联系人：
Anna Taranko，投资和公共关系主任
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
[email protected]
Oren Shuster，首席执行官
IM Cannabis Corp.
+972-77-3603504
[email protected]
Logo -
标志 -
SOURCE IM Cannabis Corp.
来源：IM大麻股份有限公司。